Neurogene

NGNE · NASDAQ

$25.40+$1.23 (+5.09%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $24.17

Latest news

Press releaseOct 20, 7:30 AM ETBusiness Wire
Neurogene Announces Upcoming Presentations Highlighting Key Differentiators of NGN-401 for Rett Syndrome at the ESGCT 33rd Annual Congress
Press releaseOct 5, 4:01 PM ETBusiness Wire
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseSep 8, 7:30 AM ETBusiness Wire
Neurogene to Participate in H.C. Wainwright 28th Annual Global Investment Conference
Press releaseSep 4, 4:01 PM ETBusiness Wire
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseAug 11, 7:30 AM ETBusiness Wire
Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates
Press releaseAug 4, 4:01 PM ETBusiness Wire
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseJul 28, 7:00 AM ETBusiness Wire
Newleos Names Rohan Palekar as Board Chairman
Press releaseJul 6, 4:01 PM ETBusiness Wire
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseJul 1, 7:00 AM ETBusiness Wire
Neurogene Inc. Announces Pricing of $125 Million Public Offering
Press releaseJun 30, 4:01 PM ETBusiness Wire
Neurogene Inc. Announces Proposed Public Offering
Press releaseJun 29, 7:00 AM ETBusiness Wire
Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome
Press releaseJun 8, 7:30 AM ETBusiness Wire
Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome
Press releaseJun 2, 4:01 PM ETBusiness Wire
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseMay 12, 4:05 PM ETBusiness Wire
Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates
Press releaseMay 12, 6:00 AM ETBusiness Wire
Neurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene Therapy
Press releaseMay 6, 4:01 PM ETBusiness Wire
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseApr 28, 7:30 AM ETBusiness Wire
Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy
Press releaseApr 20, 7:30 AM ETBusiness Wire
Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors
Press releaseApr 8, 4:01 PM ETBusiness Wire
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseMar 24, 7:30 AM ETBusiness Wire
Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates
Press releaseMar 11, 7:30 AM ETBusiness Wire
Neurogene to Participate in Stifel 2026 Virtual CNS Forum
Press releaseMar 3, 4:01 PM ETBusiness Wire
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewsMar 2, 8:07 AM ETAvi Kapoor
Yatsen Holding, Delta Air Lines, United Airlines And Other Big Stocks Moving Lower In Monday's Pre-Market Session
NewsFeb 27, 1:01 PM ETAvi Kapoor
Nasdaq Down Over 1%; Dell Shares Jump After Q4 Results
NewsFeb 27, 12:52 PM ETAvi Kapoor
Autodesk, Arlo Technologies, Beyond Meat, Netflix And Other Big Stocks Moving Higher On Friday
NewsFeb 27, 12:05 PM ET
12 Health Care Stocks Moving In Friday's Intraday Session
NewsFeb 27, 8:06 AM ETVandana Singh
Neurogene Stock Soars On FDA Breakthrough Tag For Rett Gene Therapy
NewsFeb 27, 7:05 AM ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
NewsFeb 27, 4:43 AM ETAvi Kapoor
Why Applied Optoelectronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
NewsFeb 26, 4:05 PM ET
12 Health Care Stocks Moving In Thursday's After-Market Session
Press releaseFeb 26, 4:01 PM ETBusiness Wire
Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome
Press releaseFeb 5, 7:30 AM ETBusiness Wire
Neurogene to Participate in Upcoming Investor Conferences
Press releaseFeb 4, 4:01 PM ETBusiness Wire
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Press releaseJan 12, 7:00 AM ETBusiness Wire
Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome
NewsNov 4, 2:25 PM ETVandana Singh
FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy
NewsAug 11, 8:45 AM ETVandana Singh
Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction
NewsJul 30, 11:07 AM ETVandana Singh
What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?
NewsJul 1, 1:05 PM ET
12 Health Care Stocks Moving In Tuesday's Intraday Session

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Neurogene Announces Upcoming Presentations Highlighting Key Differentiators of NGN-401 for Rett Syndrome at the ESGCT 33rd Annual Congress

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Neurogene to Participate in H.C. Wainwright 28th Annual Global Investment Conference

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Newleos Names Rohan Palekar as Board Chairman

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Neurogene Inc. Announces Pricing of $125 Million Public Offering

Neurogene Inc. Announces Proposed Public Offering

Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome

Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates

Neurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene Therapy

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy

Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates

Neurogene to Participate in Stifel 2026 Virtual CNS Forum

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Yatsen Holding, Delta Air Lines, United Airlines And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Nasdaq Down Over 1%; Dell Shares Jump After Q4 Results

Autodesk, Arlo Technologies, Beyond Meat, Netflix And Other Big Stocks Moving Higher On Friday

12 Health Care Stocks Moving In Friday's Intraday Session

Neurogene Stock Soars On FDA Breakthrough Tag For Rett Gene Therapy

12 Health Care Stocks Moving In Friday's Pre-Market Session

Why Applied Optoelectronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket

12 Health Care Stocks Moving In Thursday's After-Market Session

Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome

Neurogene to Participate in Upcoming Investor Conferences

Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome

FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy

Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

12 Health Care Stocks Moving In Tuesday's Intraday Session